Anselamimab · Amlypave

Monoclonal antibody

Also known as CAEL-101

Phase 3Mechanism not established
Phase 3underway

Evidence outlook · registrational

AL Amyloidosis: registrational readout pending

Its supporting mid-stage studies have completed. The registry records primary completion on 2025-05-10; results are not yet reported. Check News for topline announcements.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
AL Amyloidosis
NCT04504825 · Alexion Pharmaceuticals, Inc.
2020-08-25 – 2027-10-22 · AL Amyloidosis
What this study did
NCT04512235 · Alexion Pharmaceuticals, Inc.
2020-11-03 – 2027-04-08 · AL Amyloidosis
What this study did
Phase 2 (1)
AL Amyloidosis
NCT04304144 · Alexion Pharmaceuticals, Inc.
2020-03-18 – 2023-11-14 · AL Amyloidosis
What this study did
Phase 1 (1)
AL Amyloidosis
NCT07615270 · Stanford University
2026-09 – 2028-07 · AL Amyloidosis
What this study did

Competitive landscape

This drug's own stage for AL Amyloidosis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Anselamimab (Amlypave): this drugPhase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
DaratumumabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
BirtamimabDiscontinuedMonoclonal antibodyMisfolded immunoglobulin light chain (AL amyloid)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Amlypave (Anselamimab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
July 2028 (1)
Phase 1AL AmyloidosisNot yet recruiting
Est. primary completion 2028-07 · NCT07615270 · CT.gov ↗
What to watch

See the full readout calendar ↗